High-confidence AI observations with source context and evaluated outcome tracking
The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, days after the departure of former …
Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on …
The studies were "withdrawn because the authors drew broad conclusions that were not supported by the underlying data," the spokesperson …
U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Multi-Provider AI Analysis
Loading...